STML - Stemline Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/2015
Total Revenue898.1991,041.354654.16
Cost of Revenue---
Gross Profit898.1991,041.354654.16
Operating Expenses
Research Development50,242.38627,869.92129,458.676
Selling General and Administrative19,214.20712,056.898,828.843
Non Recurring---
Others---
Total Operating Expenses---
Operating Income or Loss-68,558.394-38,885.457-37,633.359
Income from Continuing Operations
Total Other Income/Expenses Net730557.156389.498
Earnings Before Interest and Taxes-67,828.394-38,328.301-37,243.861
Interest Expense---
Income Before Tax-67,828.394-38,328.301-37,243.861
Income Tax Expense--25.296-
Minority Interest---
Net Income From Continuing Ops-67,828.394-38,303.005-37,243.861
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-67,828.394-38,303.005-37,243.861
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-67,828.394-38,303.005-37,243.861